Axsome Therapeutics (AXSM) has drawn attention after recent trading, with the stock closing at US$253.77. Investors are weighing this move against the company’s central nervous system focused drug portfolio and ongoing clinical programs.

The recent 3.02% 1 day share price return, along with a 62.59% 90 day share price return and 138.84% 1 year total shareholder return, points to strong momentum as investors reassess Axsome Therapeutics’ CNS pipeline and revenue trajectory.

If Axsome’s move has your attention, this is a good moment to scan other healthcare focused AI opportunities using our 40 healthcare AI stocks

With Axsome trading at US$253.77 against an analyst price target of about US$275 and an intrinsic value estimate that implies a sizeable discount, you may wonder whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 6.1% Undervalued

Axsome Therapeutics’ most followed valuation narrative pegs fair value at about $270 per share, slightly above the latest close at $253.77. This puts the focus on whether the current price fully reflects its CNS pipeline and commercial portfolio.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Curious what sits behind that fair value gap? The most followed narrative leans on ambitious revenue expansion, margin improvement, and a richer earnings profile than Axsome delivers today.

Result: Fair Value of $270.28 (UNDERVALUED)

However, this hinges on execution, with ongoing net losses of US$188.3m and heavy reliance on Auvelity and Sunosi, which leaves the story sensitive to any commercial setbacks.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: High Sales Multiple Raises Questions

While the fair value narrative suggests Axsome is 68.1% below an intrinsic estimate, the current P/S ratio of 18.4x tells a less comfortable story. That multiple is well above the US Pharmaceuticals industry at 5.9x, the peer average at 4.7x, and even the fair ratio of 18.1x. This points to a market that already prices in a lot of success and leaves less room for disappointment if expectations shift.

For a closer look at how those ratios stack up and what they might imply for valuation risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With so much optimism already reflected in the story, are you comfortable with what the data is actually saying, or do you see something different when you look closer yourself? To pressure test the upside case and understand what the market seems most excited about, take a closer look at the 2 key rewards.

Looking for more investment ideas?

If Axsome has sharpened your focus, do not stop here. Fresh ideas from different corners of the market could round out your watchlist and help you make more informed decisions.

• Target potential mispricings by scanning 46 high quality undervalued stocks that combine solid fundamentals with room for sentiment to catch up.
• Build income resilience by reviewing 8 dividend fortresses, where yields and stability work together for investors who care about regular cash returns.
• Spot potential early standouts by checking the screener containing 20 high quality undiscovered gems before they sit firmly on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.